BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types

-The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs -BridgeBio and Helsinn have also established a non-exclusive framework agreement to identify and potentially co-develop and co-commercialize additional small molecule targeted oncology therapies -This framework agreement leverages BridgeBio’s drug discovery expertise […]

BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing

-Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the Company’s 30+ genetic disease and cancer pipeline programs into 2024 PALO ALTO, Calif., NOVEMBER 18, 2021 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases […]

BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update

–Topline results from Part A of the Phase 3 ATTRibute-CM trial of TTR stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM) expected by end of 2021 –Meaningful progress in RAS cancer portfolio with discovery of next-generation KRAS G12C dual inhibitors and novel PI3ka:RAS breakers -Advancements in gene therapy pipeline with first patient dosed in Canavan disease trial and […]

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease

-If successful, BridgeBio’s gene therapy could be the first approved therapeutic option for children born with Canavan disease, a devastating and life-threatening condition -The Canavan disease program is part of BridgeBio’s growing gene therapy portfolio, which includes clinical candidates for congenital adrenal hyperplasia (CAH) and classic galactosemia (severe GALT deficiency), and preclinical programs for TMC1 […]